Cargando…
Antibody response to COVID-19 vaccination in patients with lymphoma
Patients with lymphoma are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); therefore, evaluation of SARS-CoV-2 vaccination efficacy is essential. We conducted a prospective observational study to monitor the antibody response in 500 patients with lymphoma after SA...
Autores principales: | Narita, Kentaro, Nakaji, So, Tabata, Rikako, Terao, Toshiki, Kuzume, Ayumi, Tsushima, Takafumi, Ikeda, Daisuke, Fukumoto, Ami, Miura, Daisuke, Takeuchi, Masami, Doi, Masahiro, Umezawa, Yuka, Otsuka, Yoshihito, Takamatsu, Hiroyuki, Matsue, Kosei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859496/ https://www.ncbi.nlm.nih.gov/pubmed/35188650 http://dx.doi.org/10.1007/s12185-022-03305-z |
Ejemplares similares
-
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
por: Terao, Toshiki, et al.
Publicado: (2022) -
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
por: Tsushima, Takafumi, et al.
Publicado: (2022) -
Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022) -
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
por: Narita, Kentaro, et al.
Publicado: (2021) -
Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib
por: Ikeda, Daisuke, et al.
Publicado: (2022)